Cordis CE marks stent for use in diabetics
This article was originally published in Clinica
Warren, New Jersey-based Johnson & Johnson subsidiary Cordis has CE marked its Cypher Select Plus stent for sale in Europe for the treatment of diabetic patients. The expanded indication for Cypher Select Plus allows its use to treat coronary disease in patients with diabetes, who often present with challenging coronary anatomy. The stent has also been CE marked for use in patients with de novo lesions, in-stent restenosis, small vessels, chronic total occlusion, multivessel disease, bifurcations or acute myocardial infarction. The sirolimus-eluting device's European approval for use in diabetics follows Boston Scientific's paclitaxel-coated Taxus Liberté stent, approved for the same indication in January 2008 (see Clinica No 1289, p 18).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.